Affordable Access

Publisher Website

Lysoglycerophospholipids in chronic inflammatory disorders: The PLA2/LPC and ATX/LPA axes

Authors
Journal
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
1388-1981
Publisher
Elsevier
Volume
1831
Issue
1
Identifiers
DOI: 10.1016/j.bbalip.2012.07.019
Keywords
  • Phospholipase A2(Pla2)
  • Lysophosphatidylcholine (Lpc)
  • Autotaxin (Atx
  • Enpp2)
  • Lysophosphatidic Acid (Lpa)
  • Inflammation
Disciplines
  • Medicine

Abstract

Abstract Lysophosphatidylcholine (LPC) and lysophosphatidic acid (LPA), the most prominent lysoglycerophospholipids, are emerging as a novel class of inflammatory lipids, joining thromboxanes, leukotrienes and prostaglandins with which they share metabolic pathways and regulatory mechanisms. Enzymes that participate in LPC and LPA metabolism, such as the phospholipase A2 superfamily (PLA2) and autotaxin (ATX, ENPP2), play central roles in regulating LPC and LPA levels and consequently their actions. LPC/LPA biosynthetic pathways will be briefly presented and LPC/LPA signaling properties and their possible functions in the regulation of the immune system and chronic inflammation will be reviewed. Furthermore, implications of exacerbated LPC and/or LPA signaling in the context of chronic inflammatory diseases, namely rheumatoid arthritis, multiple sclerosis, pulmonary fibrosis and hepatitis, will be discussed. This article is part of a Special Issue entitled Advances in Lysophospholipid Research.

There are no comments yet on this publication. Be the first to share your thoughts.